Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Faina V. Alieva"'
Autor:
Irina L. Popova, Liubov Yu Vladimirova, Anna E. Storozhakova, Aza A. Agieva, Faina V. Alieva, Natalia A. Abramova, Elena S. Bondarenko, Kristina A. Novoselova, Natalia M. Tikhanovskaya, Sergey N. Kabanov, Inna Arnoldovna Novikova, Elena Yu. Zlatnik, Aleksandr B. Sagakyants, Yuriy N. Lazutin, Maria A. Teplyakova, Oleg I. Kit, Elena A. Kalabanova, Ludmila A. Ryadinskaya, Anna V. Tishina
Publikováno v:
Journal of Clinical Oncology. 39:e21035-e21035
e21035 Background: Immunotherapy with PD-1/PD-L1 check-point inhibitors (CPI) is a new trend in oncology. Their effect significantly depends on the patients` immune status. The aim of the study was to search the immunologic parameters of lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57c1a8bc5fbac1e5b7bf9218bd3e135d
https://doi.org/10.1200/jco.2021.39.15_suppl.e21035
https://doi.org/10.1200/jco.2021.39.15_suppl.e21035
Autor:
Irina L. Popova, Faina V. Alieva, Aza A. Agieva, Oleg N. Burov, Yaroslav S. Enin, Natalia M. Tikhanovskaya, Marina M. Sergeeva, Valeriya S Myagkova, Liubov Yu Vladimirova, Ludmila A. Ryadinskaya, Natalia A. Abramova, Maria A. Teplyakova, Elena Yu. Zlatnik, Kristina A. Novoselova
Publikováno v:
Journal of Clinical Oncology. 39:e15063-e15063
e15063 Background: The study of the possible antitumor activity of secondary plant metabolites either in the form of individual agents or in combination with clinically used drugs is considered as a promising direction in the therapy of malignant tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::730594e5f95625fc1110df34b6ac6d52
https://doi.org/10.1200/jco.2021.39.15_suppl.e15063
https://doi.org/10.1200/jco.2021.39.15_suppl.e15063
Autor:
A.S. Ratieva, Natalia M. Tikhanovskaya, Aza A. Agieva, Valeriya S Myagkova, Ekaterina P. Omelchuk, Irina L. Popova, Ludmila A. Ryadinskaya, Natalya N. Timoshkina, Faina V. Alieva, Dmitry Yu. Gvaldin, Liubov Yu Vladimirova, Marina M. Sergeeva, Kristina A. Novoselova, Larisa N. Vashchenko, Natalia A. Abramova, Maria A. Teplyakova
Publikováno v:
Journal of Clinical Oncology. 39:12005-12005
12005 Background: Numerous pharmacogenetic studies have led to the identification of genetic polymorphisms associated not only with the development of cardiovascular disease, but also increase the risk of complications due to the use of anthracycline
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32a3d4ef41379d4aeb893361e75230a6
https://doi.org/10.1200/jco.2021.39.15_suppl.12005
https://doi.org/10.1200/jco.2021.39.15_suppl.12005